Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer Inc PFE shares are dipping on Tuesday. The company announced a series of settlement agreements that extend the effective U.S. patent life of Vyndamax, its treatment for transthyretin‑mediated ...

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...